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Background: The lung squamous cell carcinoma survival rate is very poor despite multimodal treatment. It is
urgent to discover novel candidate biomarkers for prognostic assessment and therapeutic targets to lung
squamous cell carcinoma (SCC).
Results: Herein a two-dimensional gel electrophoresis and ESI-Q-TOF MS/MS-based proteomic approach was used
to identify differentially expressed proteins between lung SCC and adjacent normal tissues. 31 proteins with
significant alteration were identified. These proteins were mainly involved in metabolism, calcium ion binding,
signal transduction and so on. Cathepsin B (CTSB) was one of the most significantly altered proteins and was
confirmed by western blotting. Immunohistochemistry showed the correlation between higher CTSB expression
and lower survival rate. No statistically significant difference between CTSB-shRNA treated group and the controls
was observed in tumor volume, tumor weight, proliferation and apoptosis. However, the CTSB-shRNA significantly
inhibited tumor metastases and prolonged survival in LL/2 metastatic model. Moreover, CTSB, Shh and Ptch were
up-regulated in patients with metastatic lung SCC, suggesting that hedgehog signaling might be activated in
metastatic lung SCC which could affect the expression of CTSB that influence the invasive activity of lung SCC.
Conclusions: These data suggested that CTSB might serve as a prognostic and therapeutic marker for lung SCC.
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Lung cancer is the most common cancer in both men and
women, with deaths in 2012 estimated to exceed 157,300
in the United States [1]. Lung squamous cell carcinoma
(SCC) is the most common type, accounting for about
30-50% of all lung cancers patients [2]. The survival
rate of lung SCC remains low, though improvements
in surgery, radiotherapy and chemotherapy were made
[2]. Therefore, it is crucial to discover novel biomarkers
for early detection of lung SCC and monitoring of disease
progression. Furthermore, the identification of novel
therapeutic targets would also facilitate drug development
for lung SCC.* Correspondence: pxx2013@sohu.com
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reproduction in any medium, provided the orThe two-dimensional gel electrophoresis (2-DE) based
proteomics approach provides a powerful tool to analyze
the expression levels of proteins in tissue samples. This
may enable the identification of cancer related proteins
for early diagnosis, therapeutic intervention and prognostic
assessment [3,4]. Several papers have carried out proteomic
studies of lung SCC and some proteins have been identified
[5-7]. However, few biomarkers for lung SCC have been
introduced into clinical use because of insufficient
validation and the absence of prospective studies.
Moreover, there is a lack of the fundamental understanding
required for clinical applications and need a better
comprehension of the underlying biological processes.
Tumorigenesis is a complex process that involves
equal contribution from extracellular as well as intracellular
proteolytic events [8]. Invasion and metastasis of cancer
result from several interdependent processes in whichtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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B (CTSB), composed of a heavy chain of 25–26 kDa and a
light chain of 5 kDa, is a family of lysosomal cysteine
proteases and plays an important role in intracellular
proteolysis [10]. Activity of CTSB is known to be important
for tumorigenesis, angiogenesis, invasion and metastasis
[11,12]. Elevated levels of CTSB expression have been
reported in prostate cancer [13], colorectal cancer [14],
gliomas [15], melanomas [16], breast cancer [17,18].
However, few papers demonstrated that CTSB was
over-expressed in lung SCC by proteomics.
To the best of our knowledge, correction of CTSB
expression in lung SCC with prognosis and therapy has
yet to be determined. Moreover, the previous study
subject mainly consisted of Caucasian while only a few
proteomic studies on lung SCC of Asian population have
been reported. The ethnic differences among patients
may contribute to different findings. This study aimed to
determine whether expression levels of CTSB in lung
SCC of Asian population could affect proliferation,
invasion, metastasis and prognosis. Furthermore, possible
molecular mechanism was investigated.Materials and methods
Clinical specimens
Fresh human lung SCC and paired adjacent normal
tissues were obtained from 8 patients suffering lung
SCC who underwent surgical resections. Primary human
lung SCC tissues were obtained from 8 patients suffering
metastatic lung SCC by bronchoscopy. The specimens
were diagnosed histological after staining with H&E, and
the surgical pathologic stage was determined according
to the TNM classification system of the International
Union against Cancer. Detailed information of the patients
was shown in Table 1. All pairs of samples were immedi-
ately frozen in liquid nitrogen prior to experiments. This
study was approved by the Institutional Ethics Committee
of Sichuan University and informed consents were obtained
from all patients prior to analysis.Table 1 The clinical and pathologic data of patients with







1 Male 58 Poor diff. T2bN1M0 IIb
2 Male 61 Mod diff. T1N1M0 IIa
3 Female 59 Poor diff. T3N1M0 IIIa
4 Male 71 Mod diff. T2aN0M0 Ib
5 Male 49 Well diff. T1N0M0 Ia
6 Female 53 Poor diff. T3N1M0 IIIa
7 Male 66 Well diff. T1N1M0 IIa
8 Female 49 Mod diff. T2aN1M0 IIaTwo-dimensional electrophoresis and image analysis
Tissues were ground into powder in liquid nitrogen and
lysed in 1 ml lysis buffer (7 M urea, 2 M thiourea, 4%
CHAPS, BioRad, USA) containing protease inhibitor
cocktail 8340 (Sigma, St Louis, MO, USA). Samples were
then kept on ice and sonicated in five cycles of 10 s,
each consisting of 5 s sonication followed by a 10 s break.
After centrifugation at 15000 rpm for 1 h at 4°C, the
supernatant was collected and the protein concentrations
were determined using the DC protein assay kit (Bio-Rad).
Protein samples (2 mg) were applied to IPG strip (17 cm,
pH3-10NL, Bio-Rad) using a passive rehydration method.
After 16 h of rehydration, the strips were transferred to an
IEF Cell (Bio-Rad). IEF was performed as follows: 250 V
for 30 min, linear; 1000 V for 1 h, rapid; linear ramping to
10000 V for 5 h, and finally 10000 V for 5 h [19]. The
second dimension was performed using 12% SDS-PAGE
at 30 mA constant current per gel after equilibration [20].
The gels were stained using CBB R-250 (Merck, Germany)
and scanned with a Bio-Rad GS-800 scanner. Four
independent runs were made for each sample to ensure the
accuracy of analyses. The maps were analyzed by PDQuest
software Version 6.1 (Bio-Rad). The quantity of each spot
in a gel was normalized as a percentage of the total quantity
of all spots in that gel and evaluated in terms of OD. Paired
t-test was performed to compare data. Only spots that
showed significant differences (± over two fold, P < 0.05)
were selected for analysis with MS.
In-gel digestion
In-gel digestion of proteins was carried out using MS
grade Trypsin Gold (Promega, Madison, WI) according
to the manufacturer’s instructions. Briefly, spots were
cut out of the gel (1-2 mm diameter) using a razor blade,
and destained twice with 100 mM NH4HCO3/50% ACN
at 37°C for 45 min in each treatment. After drying, the
gels were preincubated in 10-20 μl trypsin solution
for 1 h. Then, 15 μl digestion buffer was added
(40 mM NH4HCO3/10% ACN) to cover gel and incubated
overnight at 37°C. Tryptic digests were extracted using
MilliQ water initially, followed by twice extraction with
50% ACN/5% TFA for 1 h each time. The combined
extracts were dried in a vacuum concentrator at room
temperature. The samples were then subjected to mass
spectrometry (MS) analysis.
Electrospray ionization quadrupole time-of-flight(ESI-Q-TOF)
analysis and protein identification
Mass spectra were acquired using a Q-TOF-MS
(Micromass, Manchester, UK) fitted with an ESI source
(Waters). Tryptic digests were dissolved in 18 μl 50%
ACN. MS/MS was performed in a data-dependent mode
in which the top ten most abundant ions for each MS
scan were selected for MS/MS analysis. Trypsin autolysis
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automatically excluded.
The MS/MS data were acquired and processed
using MassLynx software (Micromass) and MASCOT
(http://www.matrixscience.com) was used to search the
database. Database searches were carried out using the
following parameters: Database, Swiss-Prot; taxonomy,
homo sapiens; enzyme, trypsin; mass tolerance, ± 0.1 Da;
MS/MS tolerance, ± 0.05 Da; and an allowance of one
missed cleavage. Fixed modifications of cysteine
carboamidomethylation, and variable modifications of
methionine oxidation were allowed. The data format
was selected as Micromass PKL and the instrument
was selected as ESI-Q-TOF. Proteins with probability
based MASCOT scores exceeding their threshold (P < 0.05)
were considered to be positively identified. To eliminate the
redundancy of proteins appearing in the database under
different names or accession numbers, the one-protein
member with the highest MASCOT score,and belonging to
the species Homo sapiens, was further selected from the
relevant multiple-member protein family.
Real time RT-PCR
mRNA was isolated from frozen tumor tissue using
RNeasy total RNA kits (Qiagen, Hilden, Germany).
RNA concentration was evaluated by photometric
measurement at 260/280 nm. 1 μg RNA was used
for cDNA synthesis using the QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany). PCR
reactions were performed by using the Platinum®
SYBR® Green qPCR SuperMix-UDG (Invitrogen,
Karlsruhe, Germany) in the 7300 real-time PCR system
(Applied Biosystems, Darmstadt, Germany). The
paired forward and reverse primers:CTSB (forward)
5′-CCGCTCGAGGCCACCTGGCAGCTCTGGGCCT
CCCT-3′, and (reverse) 5′-ACGCGTCGACTTAGAT
CTTTTCCCAGT-3′; Shh (forward) 5′-GATGTC
TGCTGCTAGTCCTCG-3′, and (reverse) 5′-CACCT
CTGAGTCATCAGCCTG-3′; Ptch (forward) 5′-CCA
CAGAAGCGCTCCTACA-3′, and (reverse) 5′-CTGT
AATTTCGCCCCTT CC-3′. The experiment was repeated
three times.
Western blotting assay
Proteins from tissues or cells were extracted in RIPA
buffer (50 mM Tris-base, 1.0 mM EDTA, 150 mM NaCl,
0.1% SDS, 1% Triton X-100, 1% Sodium deoxycholate,
1 mM PMSF) and quantified by the DC protein assay kit
(Bio-Rad). Samples were separated by 12% SDS-PAGE and
transferred to PVDF membranes (Amersham Biosciences).
The membranes were blocked overnight with PBS con-
taining 0.1% Tween 20 in 5% skimmed milk at 4°C, and
subsequently probed by the primary antibodies: anti-CTSB
(Biovisin Res, USA), Anti-Shh and anti-Ptch (Santa CruzBiotechnology, Germany). Blots were incubated with the
respective primary antibodies for 2 h at room temperature
and washed three times in TBST. After that, the blots were
incubated with secondary antibody conjugated to HRP
for 2 h at room temperature. Target proteins were
detected by enhanced chem-iluminescence reagents
(Amersham Pharmacia Biotech, Piscataway, USA). β-actin
was used as an internal loading control. The experiment
was repeated three times.
Immunohistochemistry
The sections were stained by the Envision System-HRP
method (DakoCytomation Inc, Carpinteria, CA), according
to the kit manufacturer’s instructions. Specific antibodies
performed included anti-human CTSB and anti-human
PCNA (Santa Cruz Biotechnology, Germany). For each
section, a minimum of 5 representative fields with
well-preserved carcinoma tissue was examined at × 400
magnifications (Olympus Optical, Japan), and 200 carcin-
oma cells were counted for each field. An average for
immune-staining intensity or percentage of positive cells
was taken over these fields. In statistical analysis, with ref-
erence to Jeffrey’s study [21], staining of CTSB was scored
as the product of the staining intensity (on a scale of 0–3:
negative = 0, weak = 1, moderate = 2, strong = 3) × the
percentage of cells stained (positively recorded on an
ordered categorical scale: 0 = zero, 1 = 1-25%, 2 = 26-50%,
3 = 51-100%), resulting in a scale of 0–9. The evaluation
was performed by two independent investigators, without
any prior knowledge of each patient’s clinical information.
Any discrepancy between the two evaluators was resolved
by reevaluation and careful discussion until agreement
was reached.
shRNA plasmid vector construction
shRNA targeting human CTSB were purchased from
Santa Cruz Biotechnology, Germany . The HK sequence,
which has no homology with any mammalian sequence,
was used as negative control (NC group). Plasmids
were extracted using a Qiagen Plasmid Mega Kit
(Qiagen, Hilden, Germany) and stored at −20°C.
Cell culture and transfection
Human lung carcinoma cell line A549 and mouse Lewis
lung carcinoma cell line LL/2 (ATCC) were maintained
in RPMI 1640 or DMEM medium. The lipofectamine
2000 (Invitrogen) and shRNA were diluted in antibiotics
free media, respectively, and then combined at a ratio of
2.5:1. Cells were transfected in indicated concentrations
according to the manufacturer’s recommendation.
Tumor xenograft model and shRNA treatment
Healthy female nude mice (6–8 weeks) were injected
subcutaneously with A549 cells (5 × 106 / 100 μl PBS per
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diameters were about 0.6 cm, the mice were randomly
divided into four groups (seven per group) for caudal
vein injections. The groups were as follows: (1) PBS,
100 μl of PBS; (2) Lipo, lipofectamine 2000 62.5 μg/100 μl
of PBS; (3) Negative control, Pgenesil-2-HK-shRNA
25 μg/100 μl of PBS; (4) shRNA, Pgenesil-2-CTSB-shRNA
25 μg/100 μl of PBS. Caudal vein injections were
performed every three days, and tumor volumes were
evaluated according to the following formula: tumor -
volume(mm3) = 0.52 × length ×width2. The dissected tu-
mors were fixed in neutral buffered formalin and embedded
in paraffin, and sections (5 μm) were stained with H&E.
The animal experiment was repeated three times.
TUNEL assay
Apoptotic cells within the tumor sections were evaluated
by the terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) technique. Percent
apoptosis was determined by counting the number of
apoptotic cells and dividing by the total number of cells
in the field (5 high power fields/slide).
Therapy of lung metastatic models
Female C57BL/6 mice (6–8 weeks) were purchased from
experimental animal center of Sichuan University
(Chengdu, Sichuan province, China) and were housed in
our animal research facility. Each mouse was inoculated
with LL/2 cells (5 × 105) via the caudal vein to establish
lung metastatic model. These lung metastatic mice were
randomly assigned into the following four groups at day
12 and each mouse received the corresponding treat-
ment by caudal vein injection: (1) PBS, 100 μl of PBS;
(2) Lipo, lipofectamine 2000 62.5 μg/100 μl of PBS; (3)
Negative control, Pgenesil-2-HK-shRNA 25 μg/100 μl of
PBS; (4) shRNA, Pgenesil-2-CTSB-shRNA 25 μg/100 μl
of PBS. Caudal vein injections were performed every
three days. After 6 mice from each group were sacrificed
at day 30, lung net weight of each mouse was mea-
sured. Autopsy was performed to determine the num-
ber of the metastatic nodules of lung. The other mice
(ten mice/group) were followed for survival time. The
animal experiment was repeated three times.
Matrigel invasion assay
Cells were trypsinized and counted, after 48 h transfection
of A549 cells with PBS, Lipo, negative control and
CTSB-ShRNA. Cells (1 × 105) were counted using a
hemocytometer and cultured in the upper chamber of
a transwell insert (8-μM pores) coated with matrigel
(1 mg/mL) (Collaborative Research Inc., Boston, MA)
in the presence of 500 μl serum-free media. 700 μl
serum-supplemented media added to the lower chamber
served as a chemo-attractant and the chambers weremaintained in an incubator at 37°C. After a 48 h
incubation period, the chambers were removed from
the incubator, non-migrated cells in the upper chamber
were scraped, and migrated cells adhering to the lower
surface of transwell insert were stained with crystal violet.
Photographs of the cells were taken at a 200 magnification
with a light microscope. The cells were counted.
Data analysis and statistics
Paired t-test and one way ANOVA was used to analyze
differences between groups. Survival curves were generated
according to the Kaplan-Meier method and the statistical
analyses were performed using log-rank test. Relevance
analysis of ordinal data was performed by cross x2
test. P < 0.05 was considered significant in all analyses.
Results
Differentially expressed proteins between lung SCC and
adjacent normal tissues
2-DE was performed with lung SCC and adjacent normal
tissues from 8 patients. Image analysis was performed using
PDQuest 6.1 software, and displayed well-resolved and
reproducible protein profiles for both lungs SCC and
adjacent normal tissues (Figure 1A). 31 spots were selected
and analyzed using ESI-Q-TOF MS/MS. Because different
isoforms of a protein might have distinct functions, each
isoform/spot was considered to be a single protein for
analysis in our study. Cluster analysis revealed that the
altered proteins were involved in different biological
processes, including metabolism (40%), calcium ion binding
(13%), signal transduction (13%) and so on (Figure 1B).
Data of details was listed in Table 2. The identified proteins
were categorized into four groups according to their sub-
cellular locations. 58% of the total proteins were located in
the cytoplasm, and the remainder was situated in the
nuclear (26%), cell membrane (10%) and secreted protein
(6%) (Figure 1C). Expression profile of the 16 altered
proteins (3-fold change) was shown in Figure 1D. Among
them, CTSB was identified with significant alteration. It was
up-regulated 5.0-fold in tumor compared with pair adjacent
normal tissue (P < 0.05). Furthermore, ESI-Q-TOF-MS/MS
analysis revealed that CTSB has 11 matched peptides and a
MASCOT score of 144, as shown in Figure 2A, B, C.
Over-expression of CTSB in lung SCC
To confirm the altered expression of CTSB in lung SCC,
western blotting analysis was performed using anti-
CTSB antibody, and over-expression of CTSB was
observed in the carcinoma tissues examined (carcinoma
tissues: 2.52 ± 0.31; adjacent normal tissues: 0.42 ± 0.07;
Student’s t test, P < 0.05) (Figure 2D, E). Taken together,
our data demonstrated that CTSB was over-expressed in
lung SCC at the protein level, which was consistent with
the observation made in the 2-DE analysis.
Figure 1 Representative 2-DE gel images of lung SCC and adjacent normal tissues. (A) Fresh human lung SCC and paired adjacent normal
tissues of Asian population were obtained from 8 patients suffering lung SCC who underwent surgical resections. Total protein extracts were
separated on pH 3–10 nonlinear IPG strips in the first dimension followed by 12% SDS-PAGE in the second dimension and visualized by CBB
staining. The arrows indicate the 31 differentially expressed proteins. (B) Cluster analysis of the changed proteins revealed that the altered
proteins were involved in different biological processes, including metabolism (40%), calcium ion binding (13%), signal transduction (13%) and so
on. (C) The identified proteins were categorized into four groups according to their subcellular locations. 58% of the total proteins were located
in the cytoplasm, and the remainder was situated in the nuclear (26%), cell membrane (10%) and secreted protein (6%). (D) Expression profile of
the 16 altered proteins (3-fold change) as shown in Figure 1A. The intensities of spots were quantified using PDQuest 2-D analysis software.
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prognosis
In order to further assess their potential prognostic
value, IHC and H&E staining was performed to examine
CTSB expression in paraffin-embedded tissues (Figure 3A).
99 lung SCC tissue specimens and 29 adjacent normaltissues recruited from the archives of the pathology
department were prepared for IHC assay. Among
these 99 tumor samples (range 36–72 years), 22 were
well differentiated, 35 were moderately differentiated,
and 42 were poorly differentiated. As described above,
total staining of CTSB was scored as the product of













1 Annexin A2 ANXA2 Calcium ion binding P07355 38472/7.56 518 19 ↑5.71 ±
1.9
2 Cofilin-1 CFL1 Rho protein signal
transduction
P23528 18371/8.26 563 32 ↑3.3 ± 0.9
3 Apolipoprotein A-I APOA1 Metabolism P02647 28078/5.27 632 28 ↓2.3 ± 0.9
4 Peptidyl-prolyl cis-trans isomerase A PPIA Metabolism P62937 17881/7.82 335 19 ↑3.5 ± 1.1
5 Stathmin STMN1 Signal transduction P16949 17171/5.77 84 4 ↑4.9 ± 1.3
6 Calcium binding protein P22 CHP Calcium ion binding Q99653 22442/4.98 37 2 ↑2.1 ± 0.2
7 Myosin regulatory light chain 12A MYL12A Calcium ion binding P19105 19662/4.67 147 9 ↑2.4 ± 0.6
8 Annexin A4 ANXA4 Calcium ion binding P09525 35751/5.85 1024 39 ↓2.2 ± 0.5
9 Heat shock protein beta-1 HSPB1 Molecular chaperone P04792 22782/5.98 168 10 ↑2.3 ± 0.8
10 Glutathione S-transferase P GSTP1 Apoptosis regulation P09211 23224/5.44 342 22 ↑2.1 ± 0.4
11 Glyceraldehyde-3-phosphate
dehydrogenase
GAPDH Metabolism P04406 35922/8.58 952 36 ↑2.1 ± 0.7
12 Beta-enolase ENO3 Cell proliferation/
differentiation
P13929 46800/7.73 267 10 ↑2.5 ± 1.2
13 Fructose-bisphosphate aldolase A ALDOA Metabolism P04075 39288/8.39 406 25 ↓3.9 ± 1.4
14 Elongation factor Tu, mitochondrial TUFM Metabolism P49411 49858/7.26 662 33 ↑5.5 ± 2.1
15 Cathepsin B CTSB Migration and invasive P07858 27814/5.23 144 11 ↑5.0 ± 1.1
16 RACK1 GNB2L1 Metabolism P63244 35055/7.60 205 5 ↑4.7 ± 1.6
17 PDZ and LIM domain protein 1 PDLIM1 Structrual component O00151 36513/6.56 131 14 ↑2.1 ± 0.3
18 Acyl-CoA-binding protein DBI Metabolism P07108 10038/6.12 220 5 ↑2.3 ± 0.4
19 Complement factor H-related protein 2 CFHR2 Metabolism P36980 27896/6.52 61 10 ↓4.3 ± 1.2
20 Apoptosis regulator BAX BAX Apoptosis regulation Q07812 21184/5.08 91 9 ↑2.4 ± 0.8
21 HLA class I histocompatibility antigen,
A-25 alpha chain
HLA-A immune response P18462 38707/5.97 24 5 ↑2.2 ± 0.5
22 BMP and activin membrane-bound
inhibitor homolog
BAMBI Signal transduction Q13145 25956/8.21 255 12 ↑3.4 ± 0.9
23 mRNA-capping enzyme RNGTT mRNA splicing O60942 52533/8.3 44 9 ↓3.1 ± 0.7
24 Pyruvate kinase isozymes M1/M2 PKM2 Metabolism P14618 57805/7.95 120 14 ↑3.2 ± 1.2
25 Proteasome activator complex subunit 2 PSME2 Proteolysis Q06323 27515/5.44 327 17 ↑4.9 ± 1.5
26 Protein DJ-1 PARK7 Signal transduction Q99497 20050/6.33 566 16 ↑3.2 ± 1.3
27 Transgelin TAGLN Metabolism Q01995 22653/8.87 369 4 ↑2.8 ± 0.6
28 Glyceraldehyde-3-phosphate
dehydrogenase
GAPDH Metabolism P04406 35922/8.58 345 10 ↑2.3 ± 0.5
29 Voltage-dependent anion-selective
channel protein 2
VDAC2 Ion channel P45880 38068/6.33 47 3 ↑3.4 ± 1.0
30 Fibrinogen beta chain precursor FGB Metabolism P02675 55928/7.95 55 14 ↑3.5 ± 0.7
31 Creatine kinase B-type CKB Metabolism P12277 42644/5.35 155 9 ↓2.4 ± 0.8
Upward arrows: Up-regulated.
Downward arrows: Down-regulated.
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of cells stained (on a scale of 0–3). As shown in Table 3,
in 29 adjacent normal tissues, positive staining of CTSB
was rarely detected and total staining score was only
0.59 ± 0.95. However, the other three group including well
differentiated, moderately differentiated, poorly differentiatedshowed a remarkable increasing trend of positive
staining of CTSB, with 1.18 ± 1.26, 2.69 ± 1.65, 7.02 ± 1.94
total staining score, respectively. In conclusion, the score
of CTSB was paralleled with the increasing severity of
epithelial dysplasia. Therefore, over-expression of CTSB
was more likely to be present with poor differentiation.
Figure 2 CTSB as the representative of protein identification using ESI-Q- TOF-MS/MS. (A & B) Mass spectrogram of tryptic peptides from
spot #15. (C) Protein sequence of CTSB. The matched peptides are underlined. (D) Western blotting confirmation of the proteins CTSB,
corresponding to the spot #15. As shown, expression of CTSB was up-regulated in lung SCC compared with adjacent normal tissues. The
experiment was repeated three times. (E) The level of CTSB was 2.52 ± 0.31 in the lung SCC group, and 0.42 ± 0.07 in control (adjacent normal
tissues) (P < 0.05). β-actin was used to normalize for any differences in protein loading between lanes.
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vival rates, 99 patients were retrospectively studied.
Total staining of CTSB was still scored as the product of
the staining intensity (on a scale of 0–3) × the percentage
of cells stained (on a scale of 0–3), resulting in a staining
scale of 0–9. The survival data of patients were then
classified as weak (0–3), moderate (3.1-6), or strong
(6.1-9) staining of CTSB biomarkers. The 5-year survival
rates were 41%, 20% and 2% for weak, moderate and
strong staining samples, respectively, when CTSB wasassessed as a marker (weak VS moderate: P = 0.041;
weak VS strong: P = 0.009; moderate VS strong: P =
0.021) (Figure 3B). Multivariate analyses using Cox pro-
portional hazard model also showed that CTSB could
also be developed as a prognostic factor for lung SCC.
Analysis of patient data was conducted to study the
correlation between CTSB expression and metastatic
rates in patients. As showed in Figure 3C, the 2-year
metastatic rates were 9%, 21% and 44% for weak, moder-
ate and strong staining samples; the 5-year metastatic
Figure 3 IHC analysis of CTSB expression in lung SCC and adjacent normal tissues. (A) Staining against CTSB showed significant differences
between lung SCC and adjacent normal tissues, and overexpression of CTSB was likely to present with bad differentiation. IHC (a: adjacent normal
tissues; b: well differentiated, weakly positive; c: moderately differentiated, moderately positive; d: poorly differentiated, strongly positive.); H & E
(e: adjacent normal tissues; f: well differentiated; g: moderately differentiated; h: poorly differentiated). (B) Kaplan-Meier curves and statistics
showed the correlation between CTSB expression and decreased survival. The 5-year survival rates were 41%, 20% and 2% for weak, moderate
and strong staining samples, respectively, when CTSB was assessed as a marker (Statistical difference: weak VS moderate: P = 0.041; weak VS
strong: P = 0.009; moderate VS strong: P = 0.021). Multivariate analyses using Cox proportional hazard model also showed that CTSB could also be
developed as a prognostic factor for lung SCC. (C) Patient data showed the 2-year metastatic rates were 9%, 21% and 44% for weak, moderate
and strong staining samples; the 5-year metastatic rates were 27%, 41% and 71% for weak, moderate and strong staining samples, respectively,
when CTSB was assessed as a marker. Therefore, CTSB expression might affect metastatic capacity of lung SCC.
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strong staining samples, respectively, when CTSB was
assessed as a marker. Therefore, CTSB expression might
affect metastatic capacity of lung SCC.Down-regulation of CTSB by ShRNA
Significant suppression of CTSB expression in CTSB-shRNA
treated A549 cells was observed in 48 h. Western
blotting showed its expression could be reduced by
89.7% compared with controls (Figure 4A).Table 3 Cathepsin B immunostaining results of patients with
Tissue type Number Male Female
Adjacent normal tissues 29 14 15
Well 22 12 10
Moderately 35 16 19
Poorly 42 19 23
a Total staining of CATB was scored as the product of the staining intensity (on a sc
b P value between the four groups: Adjacent normal tissues; Well; Moderately; PoorCTSB could not inhibit tumor xenograft growth in vivo
Tumor volumes were measured every 3 days during
treatment duration until animals were sacrificed. No
significant differences in tumor growth were observed
during treatment, as shown by the tumor volume
and weight (Figure 4B). At the termination of the
experiment, tumor volume in the four groups reached
853.401 ± 187.3, 782.39 ± 153.1, 771.904 ± 139.2, 373.078 ±
82.1 mm3 for PBS, Lipo, or NC, CTSB-shRNA, respectively
(P > 0.05). The weight of tumor treated with CTSB-shRNA
also showed no significant differences compared withlung SCC
Positive rate b Intensity b Staining scorea,b
0.41 ± 0.57 0.52 ± 0.74 0.59 ± 0.95
0.68 ± 0.65 1.00 ± 0.93 1.18 ± 1.26
1.49 ± 0.56 1.80 ± 0.47 2.69 ± 1.65
2.67 ± 0.48 2.62 ± 0.49 7.02 ± 1.94
ale of 0–3) × the percentage of cells stained (on a scale of 0–3).
ly.
Figure 4 Effects of suppression of CTSB on tumor xenograft growth in vivo. (A) The A549 cells were transfected with CTSB-shRNA as
described in Materials and Methods. The protein level of CTSB was significantly down-regulated in A549 cells by CTSB-shRNA plasmids. (B) Tumor
growth curve and tumor weight after treatment with CTSB-shRNA. No statistically significant difference between CTSB-shRNA treated group and
the controls was observed (P > 0.05). The animal experiment was repeated three times. (C & D) TUNEL assay and PCNA staining. Suppression of
CTSB showed no difference in cell proliferation and apoptosis in vivo. CTSB-shRNA treated tumor did not show significantly higher percentage of
TUNEL-positive nuclei than tumors treated with PBS, Lipo, or NC (6 ± 1.3 versus 6 ± 1, 7 ± 1.5, or 7.5 ± 1.6, 6 ± 1.6) (P > 0.05). The rate of PCNA-positive
nuclei in the four groups reached 93.4 ± 6.42, 89.6 ± 7.09, 85.6 ± 9.73, 82.0 ± 7.13 for PBS, Lipo, or NC, CTSB-shRNA, respectively (P > 0.05).
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significant difference between CTSB-shRNA treated
group and the controls was observed in tumor vol-
ume, tumor weight, though tumor volume and
weight were slightly smaller in the CTSB-shRNA
treated group.
Suppression of CTSB showed no difference in cell
proliferation and apoptosis in vivo
To address tumor biological processes affected by CTSB-
shRNA, we investigated proliferation and apoptosis in vivo
by PCNA IHC analysis and TUNEL assay (Figure 4C).
CTSB-shRNA treated tumor did not show significantly
higher percentage of TUNEL-positive nuclei than tumors
treated with PBS, Lipo, or NC group (6 ± 1.3 versus 6 ± 1,
7 ± 1.5, or 7.5 ± 1.6, 6 ± 1.6, P > 0.05). The rate of
PCNA-positive nuclei in the four groups reached
93.4 ± 6.42, 89.6 ± 7.09, 85.6 ± 9.73, 82.0 ± 7.13 for PBS,Lipo, NC group and CTSB-shRNA, respectively (Figure 4D).
Thus, no statistically significant difference between
CTSB-shRNA treated group and the controls was observed
in PCNA IHC and TUNEL assay.
Reduced metastatic nodules and prolonged survival in
mice bearing experimental lung metastatic tumors by
CTSB-shRNA
The migratory and invasive properties of cancer cells are
crucial to tumor progression. We next investigated
whether CTSB-shRNA could inhibit metastatic tumors
in the lungs. As shown in Figure 5A, B, metastatic
nodules and lung weight were obviously reduced in
CTSB-shRNA treated mice. The lung weight reached
0.6 ± 0.158, 0.56 ± 0.114, 0.56 ± 0.152, 0.24 ± 0.114 for
PBS, Lipo, NC and CTSB-shRNA, respectively (P < 0.05).
Meanwhile, the treatment of CTSB-shRNA prolonged
the survival of mice with lung metastasis (P < 0.01)
Figure 5 CTSB inhibited lung metastases in vitro and in vivo. (A) The number of lung metastatic nodules was dramatically reduced in
CTSB-shRNA-treated mice compared with controls (a: PBS; b: Lipo; c: NC; d: CTSB-shRNA). (B) The lung weight of mice reached 0.6 ± 0.158, 0.56 ± 0.114,
0.56 ± 0.152, 0.24 ± 0.114 for PBS, Lipo, NC, and CTSB-shRNA, respectively (P < 0.05). The animal experiment was repeated three times. (C) Kaplan-Meier
survival curves of tumor-bearing mice demonstrated the treatment of CTSB-shRNA prolonged the survival of mice with lung metastasis (P < 0.01).
(D & E) CTSB-shRNA was effective in decreasing the invasive capacity of lung cancer cells (a: PBS; b: Lipo; c: NC; d: CTSB-shRNA). The invasive capacity
of lung cancer cells decreased nearly 80% after treatment with CTSB-shRNA by quantitative analysis (P < 0.05).
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influenced the metastatic capacity of lung cancer cells.
Suppression of CTSB remarkably decreased the invasive
capacity of lung cancer cell in vitro
After treated with PBS, Lipo, NC and CTSB-shRNA, the
invasive capacity of A549 cells was determined by the
matrigel invasion assay. The results showed that the
invasive capacity of lung cancer cells decreased nearly
80% after treatment with CTSB-shRNA by quantitative
analysis (Figure 5D, E).
Up-regulation of CTSB, Shh and Ptch in metastatic
lung SCC
The metastatic lung SCC specimens were diagnosed
histological after staining with H&E, and the clinical
stage was determined according to the TNM classification
system of the International Union against Cancer. Detailed
information of the patients was shown in Figure 6A.
Real-time quantitative RT-PCR and western blotting
analysis were conducted to examine the expression
level of CTSB, Shh and Ptch. As shown in Figure 6B,
the mRNA expression level of CTSB, Shh and Ptch in
metastatic lung SCC were significantly higher compared
with non-metastatic lung SCC and adjacent normal
tissues (p < 0.05). Furthermore, the protein expression
of CTSB, Shh and Ptch in metastatic lung SCC were
significantly higher compared with non-metastatic lung
SCC and adjacent normal tissues (p < 0.05) (Figure 6C, D).This data suggested that hedgehog signaling might be
activated in metastatic lung SCC, which could affect
expression of CTSB that could promote cancer cell
invasion.
Discussion
Lung SCC, one of the most common malignancies
worldwide, remains a major health problem with
increasing incidence rates even to date [1,2]. Although
improvements in surgery, radiotherapy and chemotherapy
were made, the survival rate of lung SCC remains low [2].
Thus, there is an urgent to identify novel prognostic and
therapeutic biomarkers for lung SCC. In the past, many
methods were used to find new tumor biomarkers. Some
studies used DNA or mRNA-based technologies, but
there are several reasons to conduct a protein-based
approach for the identification of potential tumor bio-
markers. Proteins are more diverse than DNA or RNA and
are responsible for the complexity in a biological system.
Alternative splicing and more than 100 post-translational
modifications contribute to approximately 100 different
proteins derived from a single gene [5,22].
In this study, 2-DE and ESI-Q-TOF MS/MS-based
proteomic approach was used to identify differentially
expressed proteins between lung SCC and adjacent
normal tissue. 31 proteins with significant alteration
were identified and these proteins functioned in diverse
biological processes. Previous proteomic studies that
mainly consisted of Caucasian have identified some key
Figure 6 Up-regulation of CTSB, Shh and Ptch in metastatic lung SCC. (A) Detailed information of the patients with metastatic lung SCC. (B)
The mRNA expression level of CTSB, Shh and Ptch in metastatic lung SCC was significantly higher compared with non-metastatic lung SCC and
adjacent normal tissues (p < 0.05). (C & D) The protein expression level of CTSB, Shh and Ptch in metastatic lung SCC was significantly higher
compared with non-metastatic lung SCC and adjacent normal tissues. β-actin was used as a loading control (P<0.05).
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cytokeratin 16, and cytokeratin 17 [5]. These proteins are
candidate biomarkers for the improvement of lung SCC
diagnosis and elucidation of the biology of lung SCC.
However, some proteins we found differed from pre-
viously identified proteins (Such as ANXA4, CFHR2,
CHP, CTSB and so on), which may result from ethnic
differences or tumor heterogeneity.
Among these identified proteins, CTSB was up-regulated
5.0-fold in tumor compared with pair adjacent normal
tissue (P < 0.05). Furthermore, western blotting also
showed similar results. In addition, IHC showed over-
expression of CTSB was more likely to be present
with poor differentiation of lung SCC. Analysis of
clinical data displayed over-expression of CTSB was
correlated with poor prognosis and increased incidence of
distant metastases.
Increased levels of CTSB have been reported in several
cancers, but relatively little is known about CTSB’s
involvement in lung cancer proliferation and apoptosis.
In this study, data of animal experiment indicated
that no statistically significant difference between
CTSB-shRNA treated group and the controls was observed
in tumor volume, tumor weight, TUNEL assay and PCNA
IHC. Thus, CTSB cannot directly affect proliferation and
apoptosis of lung cancer cells.
The migratory and invasive properties of cancer cells
are crucial to tumor progression. We next investigatedwhether CTSB-shRNA could inhibit lung metastatic
tumors. CTSB-shRNA reduced lung metastatic nodules
and prolonged survival in mice bearing experimental
lung metastatic tumors. Matrigel invasion assay showed
the invasive capacity of lung cancer cells decreased
nearly 80% after treatment with CTSB-shRNA.
The hedgehog pathway regulates fundamental biological
processes such as stem cell maintenance, cell differentiation,
tissue polarity, and cell proliferation [23]. Inappropriate acti-
vation of hedgehog signaling pathway has been implicated
in the development of a variety of cancers, such as breast
cancer, prostate cancer, lung cancer and so on [24-26]. It
has been reported that CTSB was a downstream target of
hedgehog signaling in breast cancer and hedgehog signaling
activated CTSB was associated with tumor invasion [27]. In
this paper, we attempted to investigate the expression level
of Shh and Ptch, two key proteins of hedgehog pathway, in
metastatic lung SCC tissues. mRNA or protein expression
level of Shh, Ptch and Ptch CTSB in metastatic lung SCC
were significantly higher compared with non-metastatic
lung SCC and adjacent normal tissues. Taken together, it
suggested that hedgehog signaling might be activated
in metastatic lung SCC, which could affect expression
of CTSB that could promote cancer cell invasion.
Conclusions
In this study, comparative proteomic analysis of lung SCC
and the adjacent normal tissues revealed 31 differentially
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http://www.molecular-cancer.com/content/12/1/125expressed proteins. Dysregulation of CTSB was associated
with aberrant metastatic capacity. Molecular mechanism
analysis suggested hedgehog signaling might be activated
in metastatic lung SCC which could affect the expression
of CTSB that could influence the invasive activity of
lung SCC cell. As a result, CTSB might be a promising
prognostic and therapy marker for human lung SCC.
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